Irritable bowel syndrome (IBS) is the commonest cause of recurrent abdominal pain in children in both more developed and developing parts of the world. It is characterized by abdominal pain that is improved by defecation and whose onset is associated with a change in stool form and/or frequency and is not explained by structural or biochemical abnormalities. A number of potential patho-physiological mechanisms have been described, but so far the exact underlying etiology of IBS is unclear. Likewise, no optimal treatment has ever been found neither for adult nor for pediatric patients. Current therapeutic options include drugs, dietary interventions and biopsychosocial therapies. The present review aims at evaluating the scientific evidence supporting the efficacy of these treatments for children with IBS.
Scientific evidence for the treatment of children with irritable bowel syndrome / Quitadamo, Paolo; Isoldi, Sara; Mallardo, Saverio; Zenzeri, Letizia; Di Nardo, Giovanni. - In: CURRENT PEDIATRIC REVIEWS. - ISSN 1573-3963. - 17:2(2021), pp. 92-102. [10.2174/1573396317666210127123330]
Scientific evidence for the treatment of children with irritable bowel syndrome
Isoldi, SaraSecondo
;Mallardo, Saverio;Zenzeri, LetiziaPenultimo
;Di Nardo, GiovanniUltimo
2021
Abstract
Irritable bowel syndrome (IBS) is the commonest cause of recurrent abdominal pain in children in both more developed and developing parts of the world. It is characterized by abdominal pain that is improved by defecation and whose onset is associated with a change in stool form and/or frequency and is not explained by structural or biochemical abnormalities. A number of potential patho-physiological mechanisms have been described, but so far the exact underlying etiology of IBS is unclear. Likewise, no optimal treatment has ever been found neither for adult nor for pediatric patients. Current therapeutic options include drugs, dietary interventions and biopsychosocial therapies. The present review aims at evaluating the scientific evidence supporting the efficacy of these treatments for children with IBS.File | Dimensione | Formato | |
---|---|---|---|
Quitadamo_Current-pharmaceutical_2021.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.66 MB
Formato
Adobe PDF
|
1.66 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.